This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Steven D. Wexner, MD
Fort Lauderdale, Fla

Arch Surg. 1999;134:511-513.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Valk et al are certainly to be congratulated for their fervent enthusiasm for this new privately held technology. The skeptic might assume that since these private physicians are based in a PET imaging center, they would bias a study by design to favor PET scan; however, it is important to put aside all such potentially cynical prejudices in favor of academic interpretation of a large number of patients carefully assessed by a variety of means and numerous statistical tests. It is particularly important to do so in light of the scope of this problem. Colorectal cancer is the second most common noncutaneous malignant neoplasm, anticipated to affect approximately 165,000 people this year.¹ It can also be anticipated that more than 40% of patients, despite seemingly curative resections, will experience a recurrence of their disease.^2-4 The most common sites of recurrence are the pelvis, liver, and lungs. . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Whole-Body PET Imaging With [¹⁸F]Fluorodeoxyglucose in Management of Recurrent Colorectal Cancer
Peter E. Valk, Elma Abella-Columna, Michael K. Haseman, Thomas R. Pounds, Ruth D. Tesar, Richard W. Myers, Hani B. Greiss, and Glenn A. Hofer
Arch Surg. 1999;134(5):503-511.
ABSTRACT | FULL TEXT